Evolving Role for BCMA-Targeted Therapies for MM

Download this slideset based on content from the annual CCO/IMF satellite symposium at ASH on BCMA-targeted treatment options for patients with relapsed/refractory multiple myeloma.
Thomas G. Martin, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.14 MB
Released: December 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics
Oncopeptides
Pfizer, Inc.
Sanofi Genzyme

Related Content

Download these expert-selected slides on treatments for early and later-stage relapsed/refractory multiple myeloma

Sagar Lonial, MD Thomas G. Martin, MD Released: October 6, 2022

A focused text activity providing an expert review of the evolution in CLL treatment during the past several years, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 6, 2022 Expired: October 5, 2023

Downloadable slideset on current best practices and standard treatments for the management of CLL/SLL in the first-line and relapsed settings, from Clinical Care Options (CCO).

Farrukh T. Awan, MD Nicole Lamanna, MD Released: October 5, 2022

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings